And inhibition of NF-κB pathway by either the IKK inhibitor PA or the proteasome inhibitor PS-341 is able to restore the anti-estrogenic effects of tamoxifen in breast cancer cells [41,42]. Here, NFKB1 is linked to breast cancer.